Investment Rating - The investment rating for the company is "Buy" and it has been maintained [5]. Core Views - The approval of the flu drug Anladiwei tablets marks a significant innovation achievement for the company, being the first global RNA polymerase PB2 protein inhibitor for flu treatment with clear mechanisms and independent intellectual property rights [1]. - The company has solidified its leading position in the respiratory drug market, with Anladiwei showing superior efficacy compared to Oseltamivir in clinical trials, reducing median time to fever relief by nearly 10% [2]. - The company is expected to improve operational efficiency and profitability through strategic focus on core business segments, with a projected net profit growth of 203% in 2025 [3]. Financial Projections - The projected net profits for 2025, 2026, and 2027 are 308 million yuan, 369 million yuan, and 422 million yuan respectively, with growth rates of 203%, 19.6%, and 14.4% [3]. - The expected earnings per share (EPS) for the years 2025, 2026, and 2027 are 0.36 yuan, 0.43 yuan, and 0.50 yuan respectively [9]. - The company’s revenue is projected to increase from 2.81 billion yuan in 2025 to 3.42 billion yuan in 2027, reflecting a growth rate of 13.9% and 10% respectively [9]. Market Position - The company is the only domestic entity with both COVID-19 and flu innovative drugs, positioning itself to enhance the treatment strategies for both diseases [2]. - The company has established a multi-modal research and development ecosystem, focusing on independent research complemented by collaborative efforts, which is expected to yield further innovative products [3].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Viewpoints - The approval of the flu drug Anladiwei tablets marks a significant innovation achievement for the company, being the first global RNA polymerase PB2 protein inhibitor for flu treatment with clear mechanisms and independent intellectual property rights [1] - The company has solidified its leading position in the respiratory drug market, with Anladiwei showing superior efficacy compared to Oseltamivir in clinical trials, reducing median time to fever relief by nearly 10% [2] - The company is expected to see a substantial increase in net profit, with projections of CNY 308 million, CNY 369 million, and CNY 422 million for 2025, 2026, and 2027 respectively, reflecting growth rates of 203%, 19.6%, and 14.4% [3] Summary by Sections Company Overview - The company has achieved a significant milestone with the approval of Anladiwei tablets, which are now the only flu treatment in China to compete directly with Oseltamivir in clinical trials [2] - The company is actively promoting the integration of COVID-19 and flu treatment strategies, enhancing its market position [2] Financial Performance - In Q1 2025, the company reported a net profit of CNY 82.61 million, a year-on-year increase of 61%, laying a foundation for high-quality development throughout the year [3] - Revenue projections for 2025-2027 indicate a recovery with expected revenues of CNY 2.81 billion, CNY 3.11 billion, and CNY 3.42 billion, respectively, with growth rates of 13.9%, 10.7%, and 10.0% [9] Research and Development - The company has established a robust R&D ecosystem, focusing on self-initiated research complemented by collaborative efforts, with ongoing clinical trials for various innovative drugs [3] - The company is advancing its dual-target (GLP-1/GIP) injection RAY1225 in the U.S. and has received ethical approval for its domestic Phase III clinical trials [3]

Market Overview - On May 23, the A-share market showed strong performance before noon but retreated in the afternoon, with the Shanghai Composite Index down 0.94% to 3348.37 points, the Shenzhen Component Index down 0.85% to 10132.41 points, and the ChiNext Index down 1.18% to 2021.50 points [2] - The total market turnover was 118.26 billion yuan, an increase of 42.9 billion yuan compared to the previous trading day [2] - Leading sectors included pharmaceuticals, automotive supply chains, and controllable nuclear fusion, while previously popular micro-cap stocks continued to adjust [2] Pharmaceutical Sector - The pharmaceutical sector experienced a strong surge, with leading innovative drug company Heng Rui Pharmaceutical listing on the Hong Kong Stock Exchange and seeing its stock price rise over 25%, boosting the entire innovative drug industry chain [3] - A-share pharmaceutical stocks rose against the trend, with companies like Hai Chen Pharmaceutical and Zhong Sheng Pharmaceutical hitting the daily limit, while Hua Sen Pharmaceutical and Cheng Da Pharmaceutical also saw gains [3] - Multiple innovative drug companies announced they would showcase their research results at the 2025 American Society of Clinical Oncology (ASCO) annual meeting from May 30 to June 3 [3] - The market's expectations for domestic innovative drugs going global were heightened following the news of a dual-antibody new drug licensing collaboration between Sanofi and Pfizer [3] - According to NextPharma, Chinese pharmaceutical companies completed 41 overseas licensing transactions in Q1 2025, totaling 36.9 billion USD, nearing the total for the entire year of 2023 [3] - From 2015 to 2024, China ranked first globally in the cumulative number of original innovative drugs developed [4] - Zhonghang Securities noted that the innovative drug industry is undergoing profound changes, with companies enhancing their core advantages and transitioning from followers to significant players in international competition [3] Micro-Cap Stocks - Micro-cap stocks initially performed well but began to adjust from mid-week, with high-profile stocks like Nanjing Port and Langsha experiencing significant fluctuations [5] - Wangzi New Materials gained attention from active market funds, achieving a limit-up on May 23 and recording five consecutive trading days of gains, effectively doubling in value [5] - According to Founder Securities, the dominance of micro-cap stocks has been a notable feature of the A-share market this year, with strong mean reversion properties observed in small-cap styles [5] - The outlook for the market suggests that the trend favoring micro-cap stocks may continue, supported by factors such as a stable capital market, ongoing economic transformation, and sustained liquidity [5]

证券代码：002317 公告编号：2025-054 广东众生药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第八届董事会第二十次会议、第八届监事会第二十次会议，于 2025 年 5 月 19 日 召开 2024 年年度股东大会，审议通过了《关于变更部分募集资金用途的议案》。 公司于 2025 年 5 月 23 日召开第八届董事会第二十一次会议，审议通过了《关于 开设募集资金专项账户的议案》。具体详见公司在巨潮资讯网（www.cninfo.com.cn） 披露的相关公告。 基于部分募投项目变更，为规范公司募集资金管理、存放和使用，切实保护 投资者权益，根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》等相关法律法规及公司《募集资金管理制度》的有关规定，公司开设 了新的募集资金专项账户用于变更后募投项目专项募集资金的存储和使用，并与 保荐机构、开户银行签署《募集资金 ...

Core Viewpoint - Guangdong Zhongsheng Pharmaceutical Co., Ltd. has decided to open a new special account for the management and use of raised funds due to changes in certain fundraising projects, ensuring compliance with relevant regulations and protecting shareholder interests [1][2]. Group 1 - The meeting of the 8th Supervisory Board was held on May 17, 2025, with three supervisors present, chaired by Mr. Tan Zhenyou [1]. - The Supervisory Board approved the proposal to open a special account for raised funds, aimed at standardizing the management, storage, and use of these funds [1]. - The decision was made after careful review and voting, with all three supervisors in favor, and no objections or abstentions [2]. Group 2 - The opening of the special account aligns with the regulatory requirements outlined in the "Guidelines for the Management and Use of Raised Funds by Listed Companies" and other relevant laws [1]. - The Supervisory Board confirmed that the new account does not harm the interests of shareholders, particularly minority shareholders [1].

证券代码：002317 公告编号：2025-054 广东众生药业股份有限公司 关于签订募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 第八届董事会第二十次会议、第八届监事会第二十次会议，于 2025 年 5 月 19 日 召开 2024 年年度股东大会，审议通过了《关于变更部分募集资金用途的议案》。 公司于 2025 年 5 月 23 日召开第八届董事会第二十一次会议，审议通过了《关于 开设募集资金专项账户的议案》。具体详见公司在巨潮资讯网（www.cninfo.com.cn） 披露的相关公告。 基于部分募投项目变更，为规范公司募集资金管理、存放和使用，切实保护 投资者权益，根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》等相关法律法规及公司《募集资金管理制度》的有关规定，公司开设 了新的募集资金专项账户用于变更后募投项目专项募集资金的存储和使用，并 ...

证券代码：002317 公告编号：2025-053 广东众生药业股份有限公司 第八届监事会第二十一次会议决议公告 第 1 页 共 1 页 广东众生药业股份有限公司（以下简称"公司"）第八届监事会第二十一次 会议的会议通知于 2025 年 5 月 17 日以专人方式送达全体监事，会议于 2025 年 5 月 23 日在公司会议室以现场表决方式召开。本次会议应出席监事 3 人，实际 出席监事 3 人，会议由公司监事会主席谭珍友先生主持，董事会秘书列席本次会 议。本次会议的召集和召开符合法律、法规和《公司章程》的有关规定。经与会 监事认真审议，以记名投票方式表决，做出如下决议： 一、审议通过了《关于开设募集资金专项账户的议案》。 基于部分募投项目变更，为规范公司募集资金管理、存放和使用，公司拟开 设新的募集资金专项账户用于变更后募投项目专项募集资金的存储和使用。经审 核，监事会认为：本次开设募集资金专项账户事项符合《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》等相关法律法规及公司《募集资 金管理制度》的有关规定，不存在 ...

一、审议通过了《关于开设募集资金专项账户的议案》。 证券代码：002317 公告编号：2025-052 广东众生药业股份有限公司 第八届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）第八届董事会第二十一次 会议的会议通知于 2025 年 5 月 17 日以专人方式送达全体董事，会议于 2025 年 5 月 23 日在公司会议室以现场和通讯表决方式召开。本次会议应出席董事 9 人， 实际出席董事 9 人。会议由公司董事长陈永红先生主持，全体监事和董事会秘书 列席会议。本次会议的召集和召开符合法律、法规和《公司章程》的有关规定。 经与会董事认真审议，以记名投票方式表决，做出如下决议： 基于部分募投项目变更，为规范公司募集资金管理、存放和使用，切实保护 投资者权益，根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》等相关法律法规及公司《募集资金管理制度》的有关规定，同意公司 开设新的募集资金专 ...

| 300705 | 九典制 | 0.44 | 3.37 | 660.10 | 3.35 | | --- | --- | --- | --- | --- | --- | | | 药 | | | | | | 600572 | 康恩贝 | 0.68 | 1.45 | 627.79 | 3.76 | | 002349 | 精华制 | 0.81 | 2.27 | 571.95 | 4.13 | | | 药 | | | | | | 002004 | 华邦健 | 0.25 | 0.80 | 571.40 | 9.29 | | | 康 | | | | | | 688553 | 汇宇制 | 1.93 | 1.88 | 555.55 | 5.80 | | | 药 | | | | | | 300086 | 康芝药 | -0.39 | 3.88 | 517.25 | 5.87 | | | 业 | | | | | | 002907 | 华森制 | 3.77 | 5.14 | 493.67 | 2.10 | | | 药 | | | | | | 000908 | *ST景峰 | 1.19 | 2.66 | 475.12 | 3.98 | ...

Group 1 - The Helicobacter pylori concept sector increased by 1.28%, ranking fifth among concept sectors, with 48 stocks rising, including New World and Haisan Pharmaceutical reaching a 20% limit up [1] - Major gainers in the Helicobacter pylori sector included Zhongsheng Pharmaceutical, *ST Sailong, and others, with increases of 8.80%, 7.82%, and 3.77% respectively [1] - The sector saw a net inflow of 599 million yuan from main funds, with 34 stocks receiving net inflows, and five stocks exceeding 50 million yuan in net inflow [2] Group 2 - The top three stocks by net inflow in the Helicobacter pylori sector were Haisan Pharmaceutical (179 million yuan), Zhongsheng Pharmaceutical (177 million yuan), and Jiaoda Onlly (128 million yuan) [2] - The net inflow ratios for Zhongsheng Pharmaceutical, Jiaoda Onlly, and Haisan Pharmaceutical were 42.93%, 18.92%, and 15.92% respectively [3] - The overall performance of the Helicobacter pylori sector was supported by significant trading volumes, with Haisan Pharmaceutical achieving a turnover rate of 39.86% [3]